Drug intelligence / Profile preview

MVP-104

Development stage: Preclinical
Lead developer: Multiverse Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MVP-104 is a monoclonal antibody currently in preclinical development by Multiverse Pharma for the treatment of neurological diseases and neuro-oncology. As of early 2024, the specific biological target of MVP-104 has not been publicly disclosed. The drug is part of Multiverse Pharma's pipeline focused on developing therapeutic antibodies for complex central nervous system disorders and brain-related cancers.

Other names: MVP-104 antibodyMVP104 antibodyMVP 104 antibody

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on MVP-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-104.

Explore the full profile